Edition:
India

Scancell Holdings PLC (SCLP.L)

SCLP.L on London Stock Exchange

7.25GBp
17 Sep 2019
Change (% chg)

-- (--)
Prev Close
7.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
658,711
52-wk High
13.90
52-wk Low
3.00

Latest Key Developments (Source: Significant Developments)

Scancell Signs First Collaboration Agreement For Avidimab
Wednesday, 4 Sep 2019 

Sept 4 (Reuters) - Scancell Holdings PLC ::FIRST COLLABORATION AGREEMENT FOR AVIDIMAB.SIGNED ITS FIRST COLLABORATION AND NON-EXCLUSIVE RESEARCH AGREEMENT WITH A ANTIBODY TECHNOLOGY CO.DEAL TO ASSESS ITS PIPELINE OF MONOCLONAL ANTIBODIES (MABS) TARGETING TUMOUR-ASSOCIATED GLYCANS.  Full Article

Scancell Says Decided to Withdraw IND Application In U.S. To Allow UK Arm OF SCIB1 Trial To Proceed
Monday, 19 Aug 2019 

Aug 19 (Reuters) - Scancell Holdings PLC ::SCANCELL HLDS - UPDATE ON THE SCIB1 PHASE 2 CLINICAL TRIAL.SCANCELL HLDS - UPDATE ON THE SCIB1 PHASE 2 CLINICAL TRIAL.SCANCELL HOLDINGS PLC - CO DECIDED TO WITHDRAW ITS IND APPLICATION IN US TO ALLOW UK ARM OF TRIAL TO PROCEED.SCANCELL HOLDINGS - WILL RESUBMIT INVESTIGATIONAL NEW DRUG APPLICATION AT LATER DATE WITH INTENT TO INITIATE CLINICAL SITES IN US.SCANCELL HOLDINGS PLC - RECEIVED NECESSARY REGULATORY AND ETHICAL APPROVALS TO INITIATE UK ARM OF SCIB1 CLINICAL TRIAL.SCANCELL HOLDINGS - U.S. FDA REQUESTED ADDITIONAL INFORMATION FROM ICHOR MEDICAL SYSTEMS ON TRIGRID 2.0 ELECTROPORATION DELIVERY SYSTEM.SCANCELL - WHILST THERE HAS BEEN EXTENSIVE DIALOGUE BETWEEN ICHOR & FDA, A TIMELY RESOLUTION TO DEVICE-SPECIFIC QUESTIONS HAS YET TO BE AGREED.SCANCELL HOLDINGS PLC - IN ORDER TO INITIATE PATIENT RECRUITMENT IN UK UNDER IND APPLICATION SUBMITTED TO FDA PRIOR APPROVAL OF IND IS REQUIRED.  Full Article

Scancell Says U.S. FDA Asks For More Information On SCIB1 Study
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Scancell Holdings PLC ::CO, ICHOR PROVIDE UPDATE ON SCIB1 PHASE 2 CLINICAL STUDY IN PATIENTS WITH ADVANCED MELANOMA.FDA REQUESTED ADDITIONAL INFORMATION, WITH RESPECT TO ICHOR'S TRIGRID 2.0 ELECTROPORATION DELIVERY SYSTEM AND ITS USE WITH SCIB1.CO, ICHOR WORKING WITH FDA TO PROVIDE NECESSARY INFORMATION TO ENABLE INITIATION OF TRIAL.ANTICIPATES PATIENT ENROLMENT INTO PHASE 2 CLINICAL STUDY OF SCIB1 WITH KEYTRUDA WILL COMMENCE IN FIRST HALF OF 2019.  Full Article

Scancell Holdings Says Entered Into Clinical Development Partnership To Develop Immunobody Vaccine
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Scancell Holdings Plc ::SCANCELL HOLDINGS PLC - ANNOUNCE THAT THEY HAVE ENTERED INTO A CLINICAL DEVELOPMENT PARTNERSHIP TO DEVELOP SCANCELL'S IMMUNOBODY® VACCINE, SCIB2.SCANCELL HOLDINGS PLC - SCIB2 IS FOR TREATMENT OF PATIENTS WITH SOLID TUMOURS, INCLUDING NON-SMALL CELL LUNG CANCER.SCANCELL HOLDINGS - UNDER TERMS OF CLINICAL DEVELOPMENT PARTNERSHIP, CANCER RESEARCH UK WILL FUND & SPONSOR UK-BASED PHASE 1/2 CLINICAL TRIAL OF SCIB2.  Full Article